Advertisement
Advertisement
U.S. markets open in 5 hours 31 minutes
Advertisement
Advertisement
Advertisement
Advertisement

Inventiva S.A. (IVA)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
12.42-0.43 (-3.35%)
At close: 12:54PM EST
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Fast Stochastic

Fast Stochastic

Previous Close12.85
Open12.49
Bid0.00 x 1200
Ask0.00 x 800
Day's Range12.42 - 12.66
52 Week Range10.52 - 19.06
Volume618
Avg. Volume4,850
Market Cap506.265M
Beta (5Y Monthly)0.90
PE Ratio (TTM)N/A
EPS (TTM)-1.38
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for IVA

Learn more
View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Inventiva S.A. - American Depos
    Daily – Vickers Top Insider Picks for 01/13/2022The Vickers Top Insider Picks is a daily report that utilizes a proprietary algorithm to identify 25 companies with compelling insider purchase histories based on transactions over the past three months.
    Rating
    Fair Value
    Economic Moat
    6 days agoArgus Research
View more
  • GlobeNewswire

    Half-Year Review of Inventiva’s Liquidity Contract with Kepler Cheuvreux

    Daix (France), Long Island City (New York), January 14, 2022 – Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of NASH, mucopolysaccharidoses (MPS) and other diseases with significant unmet medical needs, today announced the half-year report of its liquidity contract with Kepler Cheuvreux. Under the liquidity contract granted to Kepler Cheuvreux by Inventiva, the following resourc

  • GlobeNewswire

    Inventiva to present at the 40th Annual J.P. Morgan Healthcare Conference

    Daix (France), Long Island City (New York), December 16, 2021 – Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH), mucopolysaccharidoses (MPS) and other diseases with significant unmet medical need, today announced that Frédéric Cren, Chairman, CEO and cofounder of Inventiva, has been invited to present a corporate overview, followed by a Q&A

  • GlobeNewswire

    Inventiva announces positive results of clinical thorough QT study conducted with lanifibranor

    Trial conducted in 217 patients to evaluate the potential effect of lanifibranor on the QT/QTc interval in healthy subjects and to support lanifibranor New Drug Application (NDA) package in NASH Lanifibranor administered at the anticipated maximal therapeutic dose of 1200mg/day and at the supra-therapeutic dose of 2400mg/day had no impact on QT/QTc interval Daix (France), Long Island City (New York, United States), December 6, 2021 – Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-stage b

Advertisement
Advertisement